Page 1

August 16 , 2021 U UNICYCIVE Unicycive Therapeutics Announces THERAPEUTICS INC . Second Quarter 2021 Financial Results Completed initial public offering in July 2021 with gross proceeds of $ 25 million Planned meeting with the U.S. FDA in Q4 2021 to align on Renazorb program LOS ALTOS , Calif . , Aug. 16 , 2021 / PRNewswire / -- Unicycive Therapeutics , Inc. ( Nasdaq : UNCY ) , a clinical stage biotechnology company developing therapies for patients with kidney disease , today reported financial results for the second quarter ended June 30 , 2021 . LUNICYCIVE THERAPEUTICS INC . " With our recent initial public offering , we believe we are now well positioned to advance our pipeline programs for the treatment of kidney diseases , " said Shalabh Gupta , M.D. , Chief Executive Officer . " Our lead program , Renazorb , is looking to address the challenging treatment burden faced by patients suffering from hyperphosphatemia as a result of their chronic kidney disease . Our preclinical studies are ongoing to support an expedited 505 ( b ) ( 2 ) regulatory approval pathway with the U.S. Food and Drug Administration ( FDA ) . We are also advancing UNI - 494 , our novel small - molecule mitochondrial protectant product candidate for the potential treatment of acute kidney injury and chronic kidney disease , through preclinical studies to support our planned investigational new drug application with the FDA next year . With the recent funding , we look forward to accomplishing numerous milestones for our key programs . " Key Highlights and Upcoming Milestones • Completed initial public offering in July 2021 with gross proceeds of $ 25 million • Planned meeting with the U.S. FDA in Q4 2021 regarding alignment on Renazorb program • Planned completion of pre - clinical studies with UNI - 494 in the first half of 2022 Second Quarter 2021 Financial Results